Completed PHASE3 INTERVENTIONAL 1-arm NCT00208156

A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression

An Open-Label Extension Study of the Safety and Tolerability of CORLUX™ (Mifepristone) for Recurrent Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features

Sponsor: Corcept Therapeutics

Conditions Depressive Disorder, Major

Interventions Mifepristone

Updated 6 times since 2017 Last updated: Feb 14, 2012 Started: May 31, 2005 Primary completion: Nov 30, 2006 Completion: Nov 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Depressive Disorder, Major, this trial is completed. The trial is conducted by Corcept Therapeutics and has accumulated 6 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

May 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Corcept Therapeutics

Data source: Corcept Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Bellaire, United States , Bellevue, United States , Clementon, United States , Glen Oaks, United States , Las Vegas, United States , Lawrence, United States , Newark, United States , Oklahoma City, United States , Philadelphia, United States and 3 more locations